Procure a pandemic influenza vaccine (PANDFLU) and a quadrivalent seasonal influenza vaccine (QSFLU)

Ended Definitive Contract Awarded Last action

Contract number
75A50122C00007
Awardee
Awarding agency
Obligated
$63,239,785

Award facts

Contract value 100% obligated
$63,239,785.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Cost No Fee
Place of performance
San Diego, CA 92121, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00009 $0
Other Administrative Action P00008 · This contract is to advance the development of pandflu as a vaccine for the prevention of pandemic influenza infection. $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $63,239,785

About this award

Written by GovTribe AI ·

Arcturus Therapeutics, Inc. was awarded a $63.2 million definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) on September 1, 2022, to develop a self-amplifying messenger RNA (saRNA)-based vaccine platform for rapid pandemic influenza response, along with a quadrivalent seasonal influenza vaccine. The contract, which carries a cost-no-fee structure and is scheduled for completion by August 20, 2026, originated from a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA) in October 2017. BARDA's announcement sought advanced research and development of medical countermeasures against multiple threats, including pandemic influenza, with emphasis on vaccines and production platforms capable of advancing candidates toward FDA approval or licensure. No set-aside designation was applied to this award.

The contract supports ASPR and BARDA's strategic objective to develop flexible, rapid-response vaccine platforms that can be deployed during pandemic influenza outbreaks. Arcturus's saRNA technology represents an innovative approach to vaccine development, offering potential advantages in manufacturing speed and scalability compared to conventional vaccine platforms. The performance location is San Diego, California, positioning the contractor's research and development activities in a major biopharmaceutical hub. This award reflects the government's continued investment in pandemic preparedness capabilities and next-generation vaccine technologies designed to address emerging infectious disease threats.

Quick answers

Who was awarded contract 75A50122C00007?

75A50122C00007 was awarded to Arcturus Therapeutics, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 1, 2022.

How much is contract 75A50122C00007 worth?

The government has obligated $63,239,785 on 75A50122C00007.

Was contract 75A50122C00007 competed?

The extent of competition for 75A50122C00007 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login